AMA to educate doctors on value-based care models

The American Medical Association (AMA) announced a series of online resources for physicians choosing new payment models that emphasize value-based care.

The May 2 statement outlines eight education modules that promote prevention, wellness and coordinated care. The new resources are part of the AMA’s Steps Forward program, which includes interactive tools to boost delivery of quality-based care.

“With physicians facing critical decisions about new payment models, the AMA is rolling out tools to help practices of all sizes succeed and support better health outcomes for everyone,” said AMA President Steven J. Stack, MD. “The AMA’s new, comprehensive online resources will help physicians drive successful implementation as insurers introduce new payment models that reward better outcomes and treatment coordination.”

A new module on value-based care is among a variety of physician-developed resources available in the STEPS Forward collection to guide the process of implementing new payment models, including steps toward advancing team-based care, implementing electronic health records and improving care.

""
Nicholas Leider, Managing Editor

Nicholas joined TriMed in 2016 as the managing editor of the Chicago office. After receiving his master’s from Roosevelt University, he worked in various writing/editing roles for magazines ranging in topic from billiards to metallurgy. Currently on Chicago’s north side, Nicholas keeps busy by running, reading and talking to his two cats.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.